Bio-Techne stock forecast 2027–2029
MyStockButler's October 2026 analysis: The weighted case points to $64.38 by October 2029. It hinges chiefly on the $73 cash acquisition closing.
Where could Bio-Techne's shares be by 2029?
The weighted case points to $64.38 by October 2029 and hinges chiefly on the $73 cash acquisition closing. That outcome sits below the $72.55 share price.
The weighted price is $65.02 in October 2027, a 10% loss including dividends. It is $64.38 in October 2029, an 11% loss including dividends. Bear probability is 27%. Base probability is 68%; bull probability is 5%.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 27 % | 42.04 (-42 %) | 36.90 (-48 %) | 35.61 (-50 %) |
| Base | 68 % | 73.03 (+1 %) | 73.05 (+1 %) | 73.13 (+1 %) |
| Bull | 5 % | 80.10 (+11 %) | 90.25 (+25 %) | 100.61 (+39 %) |
| Weighted | 100 % | 65.02 (-10 %) | 64.15 (-11 %) | 64.38 (-11 %) |
What has to go right for Bio-Techne, and what could go wrong?
Repeated organic growth, stable segment margins and COMET placements generating recurring assay and panel orders would change the case. Repeat GMP production orders—under rules for making medicines consistently and safely for people—and sustained China demand are further tests. Bio-Techne’s investment case depends on recurring demand arriving before the Wilson Wolf cash obligation.
How much cash does Bio-Techne really make?
Stock awards are not a cash payment, but they transfer value to employees and dilute shareholders. Subtracting them produces the memo’s stricter “real free cash flow,” which improved from fiscal 2025 but remained below fiscal 2022.
| Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | |
|---|---|---|---|---|---|
| = Free cash flow | 263,223 | 256,550 | 236,104 | 216,149 | 280,364 |
| − Stock pay | 41,365 | 40,833 | 38,042 | 39,230 | 42,183 |
| = Real free cash flow | 221,858 | 215,717 | 198,062 | 176,919 | 238,181 |
| Real free cash flow, % of revenue | 18.3% | 17.7% | 17.1% | 15.6% | 21.5% |
What this means. Stock pay uses shares instead of cash, but it still reduces each shareholder’s ownership of the company.
What does an investor pay for Bio-Techne today?
Market value is what shareholders’ shares are worth; enterprise value is the operating business’s price after adding debt and subtracting cash. At $72.55 on October 25, 2026, market value is about $11.377 billion. Enterprise value is $11.312 billion. The difference suggests $64.7 million of net cash, so little of the price is simply cash on hand.
| Today (Oct 25, 2026) | |
|---|---|
| Share price | 72.55 |
| Market value (calculated) | 11,377,163.167 |
| Enterprise value (calculated) | 11,312,451.167 |
| P/E, last 12 months (calculated) | 63.1x |
| Free cash flow yield (calculated) | 2.3% |
| Real free cash flow yield (calculated) | 2.0% |